Orthocell (ASX:OCC) demonstrates potential to return function to paralysed limbs

Orthocell has been featured in The Market Herald, following the announcement of clinical data from the CelGro nerve regeneration trial demonstrating the potential to return function to paralysed upper limbs following 12 months of treatment Read the article HERE.